Kuopio, Finland

Mikael Perakyla

This inventor holds 1 USPTO granted patent. Top assignee: Flx Discoveries Oy. Active years: 2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mikael Perakyla. Retrieved from https://idiyas.com/inventor/mikael-perakyla

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mikael Perakyla: Innovator in Androgen Receptor Modulation

Introduction

Mikael Perakyla is a notable inventor based in Kuopio, Finland. He has made significant contributions to the field of medicinal chemistry, particularly in the development of non-steroidal compounds that act as androgen receptor modulators. His innovative work has the potential to impact various therapeutic areas.

Latest Patents

Mikael holds a patent for "Non-steroidal compounds as androgen receptor modulators." This invention relates to novel 4,5-dihydroisoxazoles and 4,5-dihydro[1,2,4]-oxadiazoles of formula (I). These compounds are designed for use as androgenic or antiandrogenic agents or androgen receptor modulators, along with methods for their preparation. He has 1 patent to his name.

Career Highlights

Mikael is currently associated with Flx Discoveries Oy, where he continues to explore innovative solutions in the field of drug development. His work is characterized by a commitment to advancing therapeutic options through scientific research and innovation.

Collaborations

Mikael collaborates with esteemed colleagues such as Jorma Palvimo and Tuomas Oravilahti. Their combined expertise fosters a productive environment for research and development.

Conclusion

Mikael Perakyla's contributions to the field of androgen receptor modulation exemplify the impact of innovative thinking in medicinal chemistry. His work not only advances scientific knowledge but also holds promise for future therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…